Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease | Zendy

Jeffrey L. Cummings | Zendy; Lutz Froelich | Zendy; Sandra E. Black | Zendy; Serge Bakchine | Zendy; Giuseppe Bellelli | Zendy; José Luís Molinuevo | Zendy; Reto W. Kressig | Zendy; Pamela Downs | Zendy; Angelika Caputo | Zendy; Christine Strohmaier | Zendy

Open Access

Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm²) in Alzheimers Disease

Author(s) -

Jeffrey L. Cummings,

Lutz Froelich,

Sandra E. Black,

Serge Bakchine,

Giuseppe Bellelli,

José Luís Molinuevo,

Reto W. Kressig,

Pamela Downs,

Angelika Caputo,

Christine Strohmaier

Publication year - 2012

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000340056

Subject(s) - rivastigmine , tolerability , medicine , dementia , activities of daily living , randomized controlled trial , alzheimer's disease , cognitive decline , adverse effect , donepezil , disease , physical therapy

Determine whether patients with Alzheimer's disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research